Torin 1

Name: Torin 1
Brand: Selleck Chemicals
SKU: S2827
Rating: 5 (137 reviews)

For research use only.

Catalog No.S2827

137 publications

CAS No. 1222998-36-8

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Selleck's Torin 1 has been cited by 137 publications

Nature, 2020, 10.1038/s41586-020-03056-z

PubMed: 33328639 ( click the link to review the publication )

Cell, 2020, S0092-8674(20)31627-5

PubMed: 33338421 ( click the link to review the publication )

Cell, 2020, 25;181(7):1596-1611.e27.

PubMed: 32559461 ( click the link to review the publication )

Nat Biotechnol, 2020, 38(5):638-648

PubMed: 32249828 ( click the link to review the publication )

Cell, 2019, 177(4):896-909

PubMed: 31030999 ( click the link to review the publication )

Nat Immunol, 2018, 19(12):1330-1340

PubMed: 30420624 ( click the link to review the publication )

Cell Metab, 2018, 28(3):369-382

PubMed: 30043754 ( click the link to review the publication )

Nature, 2017, 1;546(7656):168-172.

PubMed: 28538732 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

EMBO Rep, 2021, e51329

PubMed: 33480074 ( click the link to review the publication )

Autophagy, 2021, 1-14

PubMed: 33749521 ( click the link to review the publication )

Cell Signal, 2021, 80:109912

PubMed: 33388443 ( click the link to review the publication )

Nat Cell Biol, 2020, 22(10):1170-1179

PubMed: 32989246 ( click the link to review the publication )

Sci Transl Med, 2020, 12(548):eaay5691

PubMed: 32554707 ( click the link to review the publication )

Mol Cell, 2020, S1097-2765(20)30786-3

PubMed: 33271062 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5842

PubMed: 33203880 ( click the link to review the publication )

Nat Commun, 2020, 24;11(1):479

PubMed: 31980602 ( click the link to review the publication )

Autophagy, 2020, 15:1-13

PubMed: 32264736 ( click the link to review the publication )

Dev Cell, 2020, 55(3):298-313.e10

PubMed: 33171110 ( click the link to review the publication )

Cell Rep, 2020, 30(5):1400-1416

PubMed: 32023458 ( click the link to review the publication )

Cell Rep, 2020, 30(6):1835-1847

PubMed: 32049014 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038/s41418-020-00646-2

PubMed: 33100324 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3766

PubMed: 33327544 ( click the link to review the publication )

PLoS Pathog, 2020, 9;16(6):e1008568

PubMed: 32516328 ( click the link to review the publication )
Cell Death Dis, 2020, 8;5:e1214

PubMed: 24810050 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439931 ( click the link to review the publication )

Mol Nutr Food Res, 2020, 1;e1901231

PubMed: 32476238 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4488-4497

PubMed: 33415013 ( click the link to review the publication )

J Immunol, 2020, ji2000244

PubMed: 32989095 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786

PubMed: 32169890 ( click the link to review the publication )

Int J Mol Sci, 2020, 24;21(6) pii: E2240

PubMed: 32213867 ( click the link to review the publication )

Exp Cell Res, 2020, 10.1016/j.yexcr.2020.111981

PubMed: 32234375 ( click the link to review the publication )

Exp Eye Res, 2020, 203:108421

PubMed: 33359326 ( click the link to review the publication )

Cell Rep Med, 2020, 1(8):100131

PubMed: 33294856 ( click the link to review the publication )

J Clin Invest, 2020, 137585

PubMed: 32673292 ( click the link to review the publication )

Emerg Microbes Infect, 2020, 9(1):1748-1760

PubMed: 32691695 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.13703

PubMed: 32683324 ( click the link to review the publication )

bioRxiv, 2020, 2020.10.09.334128

PubMed: 33052348 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:1364147

PubMed: 32724488 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.30172

PubMed: 33230821 ( click the link to review the publication )

Nat Metab, 2020, 2(1):41-49

PubMed: 31993556 ( click the link to review the publication )

Cancer Res, 2020, 80(3):444-457

PubMed: 31722999 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4741

PubMed: 31628323 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1693

PubMed: 30979895 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5681

PubMed: 31831743 ( click the link to review the publication )

Autophagy, 2019, 15(3):493-509

PubMed: 30304977 ( click the link to review the publication )

Autophagy, 2019, 1-13

PubMed: 30957628 ( click the link to review the publication )
Autophagy, 2019, 10.1080/15548627.2019.1703353

PubMed: 31847700 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1628536

PubMed: 31203721 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 10.1073/pnas.1911393116

PubMed: 31732667 ( click the link to review the publication )

Cell Rep, 2019, 29(3):589-602

PubMed: 31618629 ( click the link to review the publication )

Cell Rep, 2019, 27(7):2075-2091.e5

PubMed: 31091447 ( click the link to review the publication )

Cell Mol Immunol, 2019, 10.1038/s41423-019-0281-6

PubMed: 31467416 ( click the link to review the publication )

Oncogene, 2019, 38(10):1639-1650

PubMed: 30337688 ( click the link to review the publication )

Oncogene, 2019, 10.1038/s41388-019-1085-y

PubMed: 31685947 ( click the link to review the publication )

Oncogene, 2019, 38(2):209-227

PubMed: 30087437 ( click the link to review the publication )

EBioMedicine, 2019, 40:151-162

PubMed: 30711516 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):399

PubMed: 31113939 ( click the link to review the publication )

Lab Invest, 2019, 99(5):648-658

PubMed: 30679758 ( click the link to review the publication )

Biochem Pharmacol, 2019, 162:191-201

PubMed: 30471247 ( click the link to review the publication )

J Biol Chem, 2019, 294(10):3760-3771

PubMed: 30617181 ( click the link to review the publication )

Life Sci, 2019, 232:116665

PubMed: 31323273 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 519(4):909-915

PubMed: 31563324 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4831

PubMed: 30446646 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5426

PubMed: 30575721 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2819

PubMed: 30026551 ( click the link to review the publication )

J Pathol, 2018, 245(2):235-248

PubMed: 29570219 ( click the link to review the publication )

PLoS Genet, 2018, 14(5):e1007369

PubMed: 29750810 ( click the link to review the publication )

Development, 2018, 145(18)

PubMed: 30126904 ( click the link to review the publication )

J Immunol, 2018, 200(8):2826-2834

PubMed: 29563176 ( click the link to review the publication )

Lung Cancer, 2018, 120:34-45

PubMed: 29748013 ( click the link to review the publication )
Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Exp Cell Res, 2018, 363(1):84-94

PubMed: 29289595 ( click the link to review the publication )

Braz J Med Biol Res, 2018, 51(6):e7080

PubMed: 29694502 ( click the link to review the publication )

Cell Res, 2017, 27(2):184-201

PubMed: 27934868 ( click the link to review the publication )

Mol Cell, 2017, 67(6):907-921

PubMed: 28844862 ( click the link to review the publication )

Mol Cell, 2017, 65(6):1029-1043

PubMed: 28306502 ( click the link to review the publication )

Nat Commun, 2017, 8:15045

PubMed: 28429794 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Autophagy, 2017, 13(8):1364-1385

PubMed: 28598230 ( click the link to review the publication )

Autophagy, 2017, 13(4):686-702

PubMed: 28121484 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

PLoS Pathog, 2017, 13(3):e1006249

PubMed: 28249048 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e2970

PubMed: 28771229 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1994

PubMed: 28515443 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13832

PubMed: 29062139 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14544-14555

PubMed: 28684424 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

J Agric Food Chem, 2017, 65(31):6625-6637

PubMed: 28697598 ( click the link to review the publication )

Radiat Res, 2017, 187(3):382-396

PubMed: 28327001 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109848-109856

PubMed: 29312653 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93688-93703

PubMed: 29212182 ( click the link to review the publication )

Oncotarget, 2017, 8(52):89527-89538

PubMed: 29163768 ( click the link to review the publication )

Oncotarget, 2017, 8(27):44550-44566

PubMed: 28562352 ( click the link to review the publication )

Protein Cell, 2016, 7(12):878-887

PubMed: 27909983 ( click the link to review the publication )
Aging (Albany NY), 2016, 8(12):3535-3551

PubMed: 28077803 ( click the link to review the publication )

Stem Cells Transl Med, 2016, 5(5):580-90

PubMed: 27025692 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(5):1428-37

PubMed: 26938669 ( click the link to review the publication )

Mol Biol Cell, 2016, 27(2):321-33

PubMed: 26582390 ( click the link to review the publication )

J Biol Chem, 2016, 291(33):17467-77

PubMed: 27339899 ( click the link to review the publication )

J Cell Physiol, 2016, 10.1002/jcp.25456

PubMed: 27301841 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

BMC Musculoskelet Disord, 2016, 17:150

PubMed: 27052304 ( click the link to review the publication )

Oncotarget, 2016, 7(5):5521-37

PubMed: 26575168 ( click the link to review the publication )

Oncotarget, 2016, 7(34):55690-55703

PubMed: 27494886 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25846574 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6559-73

PubMed: 26237138 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:15

PubMed: 25849580 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1064-74

PubMed: 25283437 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Virol, 2015, 89(1):626-42

PubMed: 25339775 ( click the link to review the publication )

Sci Rep, 2015, 5:13891

PubMed: 26403635 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.M114.621706

PubMed: 25878248 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: 25561726 ( click the link to review the publication )

Cell Signal, 2015, 27(8):1557-68

PubMed: 25936523 ( click the link to review the publication )

BMC Cancer, 2015, 15:855

PubMed: 26542945 ( click the link to review the publication )
PLoS One, 2015, 10(8):e0135614

PubMed: 26267903 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23238-48

PubMed: 26177051 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1214

PubMed: 24810050 ( click the link to review the publication )

Am J Pathol, 2014, 184(1):214-29

PubMed: 24215913 ( click the link to review the publication )

J Biol Chem, 2014, 289(43):29739-49

PubMed: 25164809 ( click the link to review the publication )

J Biol Chem, 2014, 289(25):17830-42

PubMed: 24798333 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4474-84

PubMed: 25288641 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.05.047

PubMed: 24858682 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12715-27

PubMed: 25587030 ( click the link to review the publication )

Oncotarget, 2014, 5(16):6816-31

PubMed: 25149175 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Blood, 2013, 121(18):3619-30

PubMed: 23444404 ( click the link to review the publication )

Trends Microbiol, 2013, 21(6):286-95

PubMed: 23608036 ( click the link to review the publication )

Genes Dev, 2013, 27(10):1115-31

PubMed: 23699409 ( click the link to review the publication )

PLoS One, 2013, 8(11):e80070

PubMed: 24244612 ( click the link to review the publication )

EMBO Mol Med, 2011, 3(4):189-200

PubMed: 21412983 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Targets

mTORC1 ^[1] (Cell-free assay)	mTOR ^[2] (Cell-free assay)	DNA-PK ^[2] (Cell-free assay)	mTORC2 ^[1] (Cell-free assay)	p110γ ^[2] (Cell-free assay)	View More
2 nM	4.32 nM	6.34 nM	10 nM	171 nM	View More

In vitro

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. ^[1] ^[2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. ^[1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
ETK-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXUV5RuUUN3ME2wMlAxODNyNjFOwG0>	NUfQNXl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
OCUB-M	NFzXdXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHZR4dKSzVyPUCuNFAyQTRizszN	MlPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
DOHH-2	M2TEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7Jc4xPUUN3ME2wMlAxOjJ3IN88US=>	NF\oWVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NOS-1	M13zW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDzNpZKSzVyPUCuNFAzPDJizszN	M4D2blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
L-363	NH34[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTVTWM2OD1yLkCwNlg1KM7:TR?=	M1vxT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
RL95-2	M{LBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7DRllKSzVyPUCuNFA{OiEQvF2=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
BL-70	NIXpfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M365dGlEPTB;MD6wNFM{PyEQvF2=	NULTe\|dxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
TGBC1TKB	M4\TUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPiTWM2OD1yLkCwN\|c6KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
697	M1zFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHpTmRKSzVyPUCuNFA3OzRizszN	Mn\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
RPMI-8226	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TSPWlEPTB;MD6wNFY2OSEQvF2=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
BL-41	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f3OWlEPTB;MD6wNFY6PiEQvF2=	NUjHVlMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
MRK-nu-1	M3TLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\lTWM2OD1yLkCwO\|A4KM7:TR?=	NVXzNGp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
EW-1	NXj3UIF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rDfWlEPTB;MD6wNFc1QSEQvF2=	NXrtUYdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
EVSA-T	NEjTT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPFNXMzUUN3ME2wMlAxQDl{IN88US=>	NYf6TlVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
HUTU-80	MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\DW2lEPTB;MD6wNFkzQSEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
VA-ES-BJ	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwMEC5PFQh\|ryP	Mo\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
GCIY	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwMEGwNFch\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
ES6	NFPz[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPVUI13UUN3ME2wMlAyODh\|IN88US=>	M1TPZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
NALM-6	M4KzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwMEGxNFIh\|ryP	NX\F[INvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
LB996-RCC	NXWwcYY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwMEGxN\|ch\|ryP	M{\XN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
EW-16	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljsTWM2OD1yLkCxNVkzKM7:TR?=	NFzoXW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
KALS-1	NHzTUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwMEGxPVgh\|ryP	MoTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
OPM-2	NFTOfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvP[oRKSzVyPUCuNFEzQSEQvF2=	NGn6Vpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
KU812	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rubmlEPTB;MD6wNVI6PiEQvF2=	NFjySok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
A4-Fuk	MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LsUmlEPTB;MD6wNVMyQSEQvF2=	MoTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
KGN	NHnscnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7R[WNRUUN3ME2wMlAyOzV7IN88US=>	Mlq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
KS-1	NFjM[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{C0cmlEPTB;MD6wNVM6OiEQvF2=	MonEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
no-11	MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnkVZVpUUN3ME2wMlAyOzl3IN88US=>	M{joclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
PSN1	NIfHRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFL2XoxKSzVyPUCuNFE1ODlizszN	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
SK-LMS-1	MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmD0TWM2OD1yLkCxOFE{KM7:TR?=	M1[4U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
LS-411N	M2DVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHCPGFKSzVyPUCuNFE1OzlizszN	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
HT-144	NGO4cYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEG0OVEh\|ryP	NYOyUJNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
ACN	MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMEG1JO69VQ>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
RKO	MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMEG1N\|Mh\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
CMK	M4[xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvOTWM2OD1yLkCxOVQ{KM7:TR?=	NVnQTId6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
GB-1	MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4H2c2lEPTB;MD6wNVU2OyEQvF2=	NUXkeoNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
KE-37	MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXWTWM2OD1yLkCxOVc{KM7:TR?=	MmDMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
no-10	NG[4UXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXVTWM2OD1yLkCxOVg1KM7:TR?=	NVjBdmVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
MOLT-16	M2XEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrlRWlKSzVyPUCuNFE3OjJizszN	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
HEL	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;IbWlEPTB;MD6wNVY1KM7:TR?=	NX3xWGdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NCI-H1355	M2PoUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn71TWM2OD1yLkCxOlQ3KM7:TR?=	NWLtTHNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
IST-MEL1	M4PwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDwVVdyUUN3ME2wMlAyPzd2IN88US=>	NUnp[JV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
MHH-PREB-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPSTWM2OD1yLkCxPFE5KM7:TR?=	M17pV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
ES8	M3flV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMEG4OFQh\|ryP	M4DrT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
LC-2-ad	NXv2N2NJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLDTWM2OD1yLkCyNVM4KM7:TR?=	M1X4clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
LAMA-84	NYraOlBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HoRmlEPTB;MD6wNlE3PyEQvF2=	NXHGUlRPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
BV-173	NUPJO4RWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TU[GlEPTB;MD6wNlIxOyEQvF2=	NIjT[Fg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
SW872	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjSSlBKSzVyPUCuNFIzPDdizszN	NHK4PYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
SK-UT-1	MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljiTWM2OD1yLkCyNlYyKM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
OS-RC-2	M3WzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3JXFFVUUN3ME2wMlAzOzJ\|IN88US=>	NHznNo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NCI-H747	M3nyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonoTWM2OD1yLkCyN\|Mh\|ryP	NHjMW2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
MZ2-MEL	M1fEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMEKzN\|ch\|ryP	M1LyV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
TE-11	NV;XVW04T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwMEKzO\|Ih\|ryP	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
KURAMOCHI	MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3Uc3BYUUN3ME2wMlAzPDF2IN88US=>	NVXKdpkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
HD-MY-Z	NXjVcHp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;zfmFKSzVyPUCuNFI1OjZizszN	M1[2clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
GI-1	NYP6XXM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwMEK0Olkh\|ryP	NFPOZ3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
LB1047-RCC	NGS1c4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrOXpI3UUN3ME2wMlAzPDh6IN88US=>	Ml\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
TE-12	MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDkcHd[UUN3ME2wMlAzPTVizszN	MmXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
MZ7-mel	NX;4TXp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfXTWM2OD1yLkCyOlA6KM7:TR?=	MlTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
MMAC-SF	NG\3S2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjMTHhKSzVyPUCuNFI3OzNizszN	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
A101D	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmm4TWM2OD1yLkCyOlUh\|ryP	NFHsPWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
GR-ST	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF:1WXFKSzVyPUCuNFI3PTVizszN	MmjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
MC116	NV3QUVRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMEK2PEDPxE1?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Xrd2lEPTB;MD6wNlc2KM7:TR?=	NVi3boZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
ATN-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMEK3PFkh\|ryP	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
MFH-ino	NFW4WmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXmwSXZbUUN3ME2wMlAzQDF{IN88US=>	NGK5V3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
DEL	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LWS2lEPTB;MD6wNlgyPSEQvF2=	NYixNJZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
OCI-AML2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3XTWM2OD1yLkCyPFcyKM7:TR?=	NHr4[oQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
LXF-289	NUHybZlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\VTWM2OD1yLkCyPFczKM7:TR?=	NYnVe\|M4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
IA-LM	NFfUTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwMEK5NVch\|ryP	M32ycVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
EoL-1-cell	M4jjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMEK5PVYh\|ryP	NXyxPIhMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
OVCAR-4	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXBOFJKSzVyPUCuNFMxQTRizszN	Mn;zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
ES1	M330Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLNPWRKSzVyPUCuNFMxQTdizszN	Mn7RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
CESS	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMEOwPVkh\|ryP	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
GAK	NF;xdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfxcXVrUUN3ME2wMlA{OTh4IN88US=>	M1L0UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	M3\sPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMEOyNlYh\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
TE-10	NXLYcoRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjzV2F1UUN3ME2wMlA{OzFzIN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
CCRF-CEM	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHKwd4RKSzVyPUCuNFM{PzFizszN	M1fyZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
NMC-G1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvyUmJKSzVyPUCuNFM1PDhizszN	M2LKR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
HOP-62	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHewSmpKSzVyPUCuNFM2PTZizszN	Mn:yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
SH-4	NXWyTHhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFOwN4NKSzVyPUCuNFM2QDJizszN	NY\3c4VDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NCI-H1648	M4\UUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfnTWM2OD1yLkCzOlIzKM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
EB-3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\XXGlEPTB;MD6wN\|Y1OyEQvF2=	M1LCWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
BB65-RCC	NHG0VHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\UTWM2OD1yLkCzOlkyKM7:TR?=	NH74em89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
BE-13	M4WxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MliwTWM2OD1yLkCzO\|U6KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
CP67-MEL	M2HnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnf6TWM2OD1yLkCzO\|U6KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
SW954	NWXMcHpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrhTWM2OD1yLkCzO\|kh\|ryP	NUXKXWV1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
TE-5	NFv6TFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVL0[\|Q{UUN3ME2wMlA{QDV2IN88US=>	NF;QOVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
HCE-4	NX60TY9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXDOI92UUN3ME2wMlA{QDV3IN88US=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
LC-1F	M{jQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PLUWlEPTB;MD6wN\|k5QSEQvF2=	M13MdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
TK10	NVHHepBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjyOYliUUN3ME2wMlA1ODF7IN88US=>	MonLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
SJSA-1	MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIS0c3lKSzVyPUCuNFQyQDhizszN	M4PteVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
Daudi	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2mwfWlEPTB;MD6wOFIzPSEQvF2=	MmDxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
SW982	NWnOdYQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYX2dZg2UUN3ME2wMlA1OjR4IN88US=>	M1LsfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
SF126	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMESzOlEh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
TE-15	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMES0N\|Uh\|ryP	NYXk[Zh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
COLO-684	NFPLdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnQZ5NNUUN3ME2wMlA1PTZzIN88US=>	NWf6NotjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
8-MG-BA	Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TpXGlEPTB;MD6wOFYzQSEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
NB13	NWD4eXNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUe5d45qUUN3ME2wMlA1Pzd4IN88US=>	MljTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
HCC1599	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLEbHgyUUN3ME2wMlA1QDd7IN88US=>	M1XNWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
SK-PN-DW	M3yyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwMES5OFkh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
ALL-PO	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M172VWlEPTB;MD6wOFk2PiEQvF2=	NXjNdZpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NB6	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjnSo1KSzVyPUCuNFUzPzFizszN	NWXiWm1TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
IST-SL2	Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFThU2xKSzVyPUCuNFU{PjJizszN	NYnvOmYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
BB30-HNC	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwMEW3N{DPxE1?	MnzaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
SW962	NXPSbJFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTBwMEW3OlMh\|ryP	NHGwZ2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
TGBC24TKB	NGXBbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwMEW3PVkh\|ryP	MoO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
KINGS-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHyc25KSzVyPUCuNFU5ODNizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
HC-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3[wSGlEPTB;MD6wOVgzPyEQvF2=	NFLubXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
RS4-11	NFrXRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUi4U\|VrUUN3ME2wMlA2QTN6IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
LS-123	NHPodIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn23TWM2OD1yLkC1PVQzKM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
A3-KAW	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYP2[lNqUUN3ME2wMlA3OjJ3IN88US=>	MkfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
SNB75	M4jrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjDSVV5UUN3ME2wMlA3OzRzIN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
SR	NWnGNox1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELDRlVKSzVyPUCuNFY{PzRizszN	M4T1[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
LOUCY	NYDXRVFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rmUmlEPTB;MD6wOlM6PCEQvF2=	NYS1eGdTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
K5	NVvxdG1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HpSmlEPTB;MD6wOlQxOyEQvF2=	M3zmOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
Becker	MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHoTWM2OD1yLkC2OFIh\|ryP	NYjpPHRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
CTV-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHEcIpKSzVyPUCuNFY2PDhizszN	Mm[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
KLE	MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwME[1PFQh\|ryP	MnPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
MZ1-PC	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXy[GZHUUN3ME2wMlA3PTl6IN88US=>	NIj5OGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
MOLT-4	NFvCVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvo[WNKSzVyPUCuNFY3ODVizszN	MoHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
MLMA	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW[w[ok1UUN3ME2wMlA3PzhizszN	MoDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
A388	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[yUmpKSzVyPUCuNFY5QTNizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
MV-4-11	NFf5fFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwME[5PVUh\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
DSH1	NYPjeGdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{O3WmlEPTB;MD6wO\|E4OyEQvF2=	MmDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
MONO-MAC-6	M1vZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mny5TWM2OD1yLkC3NlEzKM7:TR?=	M1[3bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
ARH-77	NFS2VXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwMEeyO\|gh\|ryP	NVT6N4xLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
LB771-HNC	M3XuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7WTWM2OD1yLkC3OVQ6KM7:TR?=	MmezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
PF-382	M1\KXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{G4NGlEPTB;MD6wO\|U3QSEQvF2=	M3zwZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
KM12	NGXodFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTMWo5mUUN3ME2wMlA4PjRizszN	MmTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
HAL-01	MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1iy[WlEPTB;MD6wO\|Y2QCEQvF2=	MkjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
RPMI-8402	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\XbGlEPTB;MD6wO\|c5QSEQvF2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
OMC-1	MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMEe4NFQh\|ryP	NXrVUYxORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
HT	NFHkTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWT1[2ZsUUN3ME2wMlA5KM7:TR?=	NILuRZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
QIMR-WIL	NGjlWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HuZmlEPTB;MD6wPFA2PSEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
KNS-42	M4[3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPxSnVKSzVyPUCuNFgzODNizszN	M1HvclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
BC-3	NUPuUXc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorUTWM2OD1yLkC4NlA1KM7:TR?=	NE\Dc4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
ES4	MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH[z[25KSzVyPUCuNFgzQTZizszN	NGHHe\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NCI-H23	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTVPWV4UUN3ME2wMlA5PDRizszN	M2fIUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
LB2518-MEL	MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfIVoppUUN3ME2wMlA5Pjl4IN88US=>	NXHhUoNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
LC4-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TLeGlEPTB;MD6wPFc{QCEQvF2=	NWXtTnBQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
SIG-M5	NVTMNnhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvZS\|hUUUN3ME2wMlA5QTB2IN88US=>	NHrXXoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
LP-1	M{G2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPLTWM2OD1yLkC4PVM5KM7:TR?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
TE-8	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPmbphKSzVyPUCuNFkxOTZizszN	M3nSbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
K-562	NXzUcJZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXiN4dKSzVyPUCuNFkyOiEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	M4\iZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwMEmxOVMh\|ryP	Mn\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
DU-4475	MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwMEmxOlUh\|ryP	NELD[oQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
RXF393	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfBRlJKSzVyPUCuNFk1PjJizszN	NHjLOGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NB5	NVTofWNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXiXnZKSzVyPUCuNFk3OjVizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
A704	M3H3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMEm3OFEh\|ryP	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
SF268	M{HRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHZRWZYUUN3ME2wMlA6QDJ3IN88US=>	NWLtcoFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
UACC-257	MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvxTWM2OD1yLkC5PFM{KM7:TR?=	NFPrNVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
L-428	NH62fWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\pbFV2UUN3ME2wMlExOzJizszN	MmPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
ST486	M13ycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3ETWM2OD1yLkGwOlA3KM7:TR?=	M1jqO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
SK-MM-2	M3nJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvDTWM2OD1yLkGwO\|A6KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
COR-L279	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMUC4N\|Ih\|ryP	NIHSWm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
JiyoyeP-2003	NXLVe\|A6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1W0fWlEPTB;MD6xNFg1OyEQvF2=	NFrFeGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
GT3TKB	MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3NXI1xUUN3ME2wMlExQTF6IN88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
HCE-T	MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnywTWM2OD1yLkGwPVQh\|ryP	NHfJ[JI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
SBC-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDITWM2OD1yLkGxNVE6KM7:TR?=	M3X1d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
KNS-81-FD	M{e0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HYemlEPTB;MD6xNVI4OyEQvF2=	NFLq[mM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NCI-H2126	Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMUGzPVQh\|ryP	NH6zVnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
EM-2	NUfRPHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHFcW5xUUN3ME2wMlEyPTJ7IN88US=>	M{HSNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
JAR	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vyOWlEPTB;MD6xNVU6QCEQvF2=	NVOyXWdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NB17	NV\ZbVZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnyTWM2OD1yLkGxOlUzKM7:TR?=	NVW2WYVWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
LB647-SCLC	M2jGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEeyeoZKSzVyPUCuNVE4ODVizszN	M{fB[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
CAL-148	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwMUG4JO69VQ>?	NFvUTlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
K052	M{LNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnsVG1KUUN3ME2wMlEyQDVzIN88US=>	NFfjU5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
KARPAS-299	NUniTJJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nqWWlEPTB;MD6xNlI{OyEQvF2=	M2fNO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
KARPAS-422	NXn0Oot4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwMUK0N\|Ih\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
LOXIMVI	NEDtfGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTLTWM2OD1yLkGyOVE2KM7:TR?=	NYS1doZnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
SCC-3	NFWwS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVKzfHFQUUN3ME2wMlEzQDVzIN88US=>	NIfITXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
LU-139	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHZTWM2OD1yLkGyPVc2KM7:TR?=	M4[wNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
COLO-320-HSR	NWftdIpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LPcmlEPTB;MD6xN\|A5PiEQvF2=	NHj5clQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
ONS-76	MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEThVGxKSzVyPUCuNVMyOyEQvF2=	M4PHcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
U-266	M1XFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMUOyOFUh\|ryP	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
HH	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTESJM6UUN3ME2wMlE{PTN3IN88US=>	NHr2RWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
BB49-HNC	NEO2T2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfocoZMUUN3ME2wMlE{PTh5IN88US=>	MmeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
NCI-SNU-5	MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DLTGlEPTB;MD6xN\|U6PiEQvF2=	M3Ta[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
C2BBe1	NV\GTGNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfxTWM2OD1yLkGzO\|Q3KM7:TR?=	MkD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
ML-2	Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXO4NW5rUUN3ME2wMlE{QTV\|IN88US=>	NIGyc3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
SCH	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMUO5O\|Qh\|ryP	NU\zSI5YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NCI-H82	NF7wd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHJTIRiUUN3ME2wMlE1OTB2IN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
MDA-MB-134-VI	NF\OS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\2SGNKSzVyPUCuNVQzPTJizszN	NXj5U\|M3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
SK-N-DZ	NWfW[YV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUi5ZXd[UUN3ME2wMlE1PzF7IN88US=>	NInZdVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
HL-60	M{S1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{i0ZWlEPTB;MD6xOFkzKM7:TR?=	NG\5fFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
LB373-MEL-D	NHKxRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PDTmlEPTB;MD6xOVU{QSEQvF2=	M3WyNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
LB831-BLC	M4rsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVL6NGF2UUN3ME2wMlE3ODd4IN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	M3u2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLhTWM2OD1yLkG2NVAyKM7:TR?=	MkK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
IMR-5	NVLPWo5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3qTWM2OD1yLkG2OFg{KM7:TR?=	NHvZcHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
Calu-6	M171WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXKTWM2OD1yLkG2OVM4KM7:TR?=	NGf1WXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NCI-H1882	NVT6dHllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwMU[3Nlgh\|ryP	NYf1bJpwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NCI-H446	NWTjfmt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUD5W5BPUUN3ME2wMlE3QDlzIN88US=>	M{XKO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
GI-ME-N	M{j4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGL1ZlhKSzVyPUCuNVgxOiEQvF2=	M1\TZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
MPP-89	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETJZZpKSzVyPUCuNVgyOjFizszN	M1ywTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
CGTH-W-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfjOY81UUN3ME2wMlE5PDN4IN88US=>	Mn\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
MEG-01	NHTVd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwMUi2Nlgh\|ryP	NXTrWYtXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NCI-H748	NVnVNXFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMUi5NVEh\|ryP	NX3kS3NpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
COLO-829	M1qzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGeze5NKSzVyPUCuNlA3PzNizszN	NIPsdok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
GOTO	NXXwVGY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TDfWlEPTB;MD6yNFc{KM7:TR?=	NVHYN4ZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
EW-3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDQTWM2OD1yLkKxO\|E5KM7:TR?=	MmHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
KY821	M{\lZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXq0b2RNUUN3ME2wMlIzODR3IN88US=>	M1HUNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
CTB-1	NETwc\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XrSGlEPTB;MD6yNlIzQCEQvF2=	NH\XUpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
TALL-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\CRWlEPTB;MD6yNlkzOSEQvF2=	NIDsOWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NCI-H209	NELiUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDNNJFSUUN3ME2wMlIzQTZ{IN88US=>	M2HDblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
IST-MES1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TzZmlEPTB;MD6yN\|UyKM7:TR?=	MkewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
DMS-114	NWfz[ItLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfifFBKSzVyPUCuNlM6QTNizszN	NHHPVYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
SNU-C2B	NYLRUJBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\0XmlEPTB;MD6yOFMyPiEQvF2=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
DG-75	MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HIV2lEPTB;MD6yOlE6PSEQvF2=	NH25cJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
D-336MG	NX3vN29kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMk[1OVch\|ryP	NX72WFV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
KMOE-2	NYr5b2pqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMke1N\|gh\|ryP	NELiN3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NB1	NH24V5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwMke5NlYh\|ryP	NH;TU4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
RH-1	NH35[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnyTWM2OD1yLkK3PVg6KM7:TR?=	M2\PfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
TE-1	NHPVeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwMki0O\|kh\|ryP	NI\4bY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
RPMI-6666	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{GzcWlEPTB;MD6yPFg1KM7:TR?=	NFzaWXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
TE-9	NG\0VGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDPZXFKSzVyPUCuNlg6QDVizszN	NXjNVllKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
BT-474	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWe2ZXVSUUN3ME2wMlI6OzN2IN88US=>	M3\5NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
COLO-668	NVLGPZZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInNWJNKSzVyPUCuNlk1OjlizszN	M{GwSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
NCI-H1581	NXrUS2Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDzUJRKSzVyPUCuNlk3QDlizszN	M1;nNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
MN-60	Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwMkm5NFUh\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
L-540	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{D2UWlEPTB;MD6zNFA5OSEQvF2=	NXnubplFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
MOLT-13	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwM{CxPFMh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
NCI-SNU-16	NGPFOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLqUm5HUUN3ME2wMlMxOjB3IN88US=>	NYTZ[ZNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NCI-H64	NUftUm9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfITWM2OD1yLkOwN\|MyKM7:TR?=	Ml3XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
CP66-MEL	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfyUmFKSzVyPUCuN\|E1OTVizszN	NYPNeZBIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NB69	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvBTWM2OD1yLkOyNVg5KM7:TR?=	M3zFZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
NCI-H2196	M{W1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPDTmNKSzVyPUCuN\|MxOzZizszN	MnziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
MHH-CALL-2	NH\wfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwM{O0Olgh\|ryP	NIXCVIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
HCC2157	M1y5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwM{O5OVQh\|ryP	NVjEWZdxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
LS-1034	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwM{[zPFgh\|ryP	M{XaNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
BOKU	M2HEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDDNIJJUUN3ME2wMlM4OTl7IN88US=>	Mnr2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
GDM-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwM{eyN\|Qh\|ryP	MoTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
TGW	M2\4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjiSIxbUUN3ME2wMlM4PDV\|IN88US=>	NVzN[\|ZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
SNU-C1	NXPBUYpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnuzTWM2OD1yLkO4NlE2KM7:TR?=	MkjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
LS-513	M{TQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3W1eGlEPTB;MD6zPVA4OSEQvF2=	NV\VdFF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NOMO-1	MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXDRoVKSzVyPUCuN\|k6PzFizszN	NGTnUnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
MS-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVK4cFJVUUN3ME2wMlQxOTd5IN88US=>	NH7yOo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
EKVX	NWLuSYRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDSeVJWUUN3ME2wMlQ1PDZzIN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
SK-MEL-2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[3R\|lKSzVyPUCuOFY1KM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
HCC1187	MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\zTWM2OD1yLkS2O\|Y5KM7:TR?=	NGryOGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
HCC2218	NF7qZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorvTWM2OD1yLkS3NlI4KM7:TR?=	NELQU\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NCI-H187	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLre4NyUUN3ME2wMlQ4QDRizszN	M2nnbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
DB	NF3I[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DXUmlEPTB;MD61NFA2PSEQvF2=	NYXLU2p4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NCI-H69	M4rNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwNUCyOFch\|ryP	M4f2TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
NCI-H1694	NHnjVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwNUC2PVch\|ryP	MkTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
CA46	NV3UO2pTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXv1[nVxUUN3ME2wMlUxQTF5IN88US=>	NXP3Zm1oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
EHEB	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3ZTpNKSzVyPUCuOVEyQTNizszN	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
NCCIT	NWLYToZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPYTWM2OD1yLkW0N\|IyKM7:TR?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
NCI-H720	NVPXXG1bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXyTWM2OD1yLkW0PVYzKM7:TR?=	M3flcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
LU-134-A	NXe4T\|FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWq0dY1LUUN3ME2wMlU2Ojl4IN88US=>	NWnqRW13RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
MC-CAR	NEfBfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TqcmlEPTB;MD61OVQ{OSEQvF2=	NG\XbpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NEC8	M2WyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHYfm9lUUN3ME2wMlU3OTd{IN88US=>	Mnz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
NCI-H524	NELGR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PON2lEPTB;MD61PFc1QCEQvF2=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
NCI-H1963	NXrifZpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnVd2dVUUN3ME2wMlYzPThizszN	NFv0Z4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
SU-DHL-1	M4PoZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwNkS1NlYh\|ryP	M4HzRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
NCI-H1522	NUDqOopkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTab5JKSzVyPUCuOlQ5QDNizszN	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
NCI-H1155	NIXZcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILoe4JKSzVyPUCuOlU{PSEQvF2=	MnXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
D-263MG	MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwNk[xNFEh\|ryP	M{fheVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
TE-6	M2LWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwNkixNFQh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
NCI-H1417	NX7VdnB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLLPYJKSzVyPUCuOlk4OTFizszN	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
NCI-H510A	MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfWcHpIUUN3ME2wMlc4OjN4IN88US=>	NETUWYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
KARPAS-45	NXXvV3lFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjNXWNoUUN3ME2wMlc5OjN3IN88US=>	MnvjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
IST-SL1	MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NICwZmtKSzVyPUCuPFU5OjVizszN	M3XaPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
COLO-824	NF\oVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwOEe4N\|Uh\|ryP	NHGzb\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NCI-H526	Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7ncmZKSzVyPUCuPVA6PThizszN	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
NCI-H719	Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwOU[2OVch\|ryP	NXm0Z2V{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
SF539	NX3XXZo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjhTWM2OD1yLkm4N\|k3KM7:TR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
NKM-1	NWfWcnRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPlTWM2OD1yLkm4OlY{KM7:TR?=	Ml7CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
A253	NHjwXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwOUi4PFUh\|ryP	NWDHUZdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
TE-441-T	NVTNUWhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU[3R3NFUUN3ME2xMlA1OzVizszN	NHThe3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
COR-L88	NEnBdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPWTmdKSzVyPUGuNVE{PTRizszN	NYHW[pVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
CPC-N	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXCRlN5UUN3ME2xMlE2QDh6IN88US=>	NUXDUpgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NCI-H2107	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfCTWM2OD1zLkG3NlYyKM7:TR?=	NHLNV489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
ECC4	M2W0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TlUWlEPTB;MT6xPFY6OyEQvF2=	M1OxVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
NCI-H2141	MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETDZ2ZKSzVyPUGuNVkzQTlizszN	NUe4fI5oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NCI-H1770	M{HXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfGTWM2OD1zLkOyPVI5KM7:TR?=	MlPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
NCI-SNU-1	NFz1SGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPQ[VdkUUN3ME2xMlM{ODRizszN	MkfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
LU-165	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTFwNEW0Olch\|ryP	Ml\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
Raji	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrDNXBKSzVyPUGuOFczPTlizszN	NHLOPVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
EW-24	NI\sb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mne3TWM2OD1zLkW0OlE6KM7:TR?=	NYTpVZppRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
KP-N-RT-BM-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPFTWM2OD1zLkW2OVUyKM7:TR?=	NHH1SoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
SK-MEL-1	NYTMNFJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3X3SGlEPTB;MT62OFg4PyEQvF2=	NEfJdIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
SCLC-21H	M{TqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfrO5MzUUN3ME2xMlY3PjVzIN88US=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
SIMA	NF:ydXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTFwNkiyN\|Mh\|ryP	NIL0PYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NCI-H1304	MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTFwN{C3OlUh\|ryP	NGrMTW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
REH	NIC3[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DCVWlEPTB;MT63NVA4QCEQvF2=	NH\KT5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
KP-N-YS	NEHmbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFK5O25KSzVyPUGuPVM2PTFizszN	M4rUVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
DMS-153	MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvRV5pqUUN3ME2xMlk4PTlizszN	M{\PR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
NB10	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTJwMkC4O\|gh\|ryP	MmDMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
NCI-H345	M{XYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHoVWluUUN3ME2yMlYyQTB3IN88US=>	NUTPZ\|N[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
SK-N-FI	MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HOXmlEPTB;Mj63OVM5OSEQvF2=	MkDQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
NCI-H1092	MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDKTWM2OD1{Lkm1N\|k1KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
KM-H2	NGLFemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTNwNkWzPVYh\|ryP	Mmi1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
KG-1	NH\xZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHjTWM2OD1\|LkexOlg5KM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
D-283MED	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTNwN{W4O{DPxE1?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
LU-65	M4e4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;WTWM2OD12LkGxOFg2KM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
MSTO-211H	MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLqTWM2OD12LkG4PFk5KM7:TR?=	Moq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
NCI-H2081	NXLDXlRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXHTWM2OD12LkK5NVc1KM7:TR?=	MkfDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
D-247MG	M33QOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlv1TWM2OD12LkSzNVkyKM7:TR?=	NXTIV\|hFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
P31-FUJ	MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfCTWM2OD12LkS1NFE6KM7:TR?=	NVTj[m9YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
DMS-79	NUCzT41TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTRwOUOxPFMh\|ryP	NFvTTWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
KASUMI-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrRTWM2OD12Lkm3OVA6KM7:TR?=	NYWwOXRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
JVM-3	M1vj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;ZOFE1UUN3ME21MlI2ODF2IN88US=>	MkSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
LAN-6	MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV32eJFNUUN3ME21MlUyPzN4IN88US=>	M1\CTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
DJM-1	MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DlUGlEPTB;NT61OlAzQSEQvF2=	MmnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
JVM-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXXTWM2OD13Lk[3NFkzKM7:TR?=	M2HRTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
U-87-MG	NYnkOWdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnvc29WUUN3ME21Mlg6QTZ2IN88US=>	M{\4[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
SHP-77	M{TONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTVwOUS5Nlgh\|ryP	MlfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
RPMI-8866	M2HMSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrGTWM2OD14LkK3NFE{KM7:TR?=	NVTmU2ZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
ES7	NUXHVHhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfCUmVzUUN3ME22MlM6QTJ2IN88US=>	NGLJcJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
WSU-NHL	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\uVopKSzVyPU[uOVE3ODlizszN	M1L3cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
CAS-1	MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXHNnVXUUN3ME23MlA6PzR7IN88US=>	M3XnOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
MHH-NB-11	M4XXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmWyTWM2OD16LkKzNVUzKM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
ES5	NUjJUVF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkewTWM2OD17LkWyNlg3KM7:TR?=	M4PxflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
HDLM-2	M4rzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjTWog{UUN3ME25Mlk2QTB{IN88US=>	NEjFU\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NCI-H2171	NXK3W2JbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTFyLkW5Nlch\|ryP	NVPiNIIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
LNCaP-Clone-FGC	NEXrXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTFzLkO3NVgh\|ryP	Ml35QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI2PjR3OT:nQnNCVkeHUkyvZV4>
NCI-H1395	M4ftc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTVTWM2OD1zMj6yOlk6KM7:TR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
NCI-H1436	M1e0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonqTWM2OD1zMz6zNVk2KM7:TR?=	NGrZWJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
RCC10RGB	M1rX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTRdGZXUUN3ME2xN{4{OjJzIN88US=>	NFvyN\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
SW684	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\FeFhUUUN3ME2xN{46Pzl5IN88US=>	M3\xPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
NCI-H1650	MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTkOHRyUUN3ME2xOU4xPDR5IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
EW-13	MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LLNmlEPTB;MUWuNlAzOSEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlU3PDV7Lze+V2FPT0WUPD;hQi=>
EC-GI-10	M2noPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHMTWM2OD1zNT64OlQ1KM7:TR?=	M4L3Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
CHP-126	Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TPU2lEPTB;MUeuNVkyQCEQvF2=	NGTHZ\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
NCI-H226	NVfZPYVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MluzTWM2OD1zOD6wOFA{KM7:TR?=	NYXPT5g3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
NCI-H1838	M2PQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYewVYdnUUN3ME2yNE4yQDR6IN88US=>	NIPEPYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjV4NEW5M{c,W0GQR1XSQE9iRg>?
EW-11	MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zQfWlEPTB;MkSuNlcyQCEQvF2=	NVzLeGtERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ3NkS1PU8oRlODTlfFVlww[T5?
EB2	Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\5TWM2OD1\|MT61N\|E5KM7:TR?=	M{Tw[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
D-502MG	NEPaUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUn3TYR3UUN3ME20N{46OjJ7IN88US=>	M4\wOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
U-698-M	NYHFVodbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTR6Lki2O\|Eh\|ryP	M{jqOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
ES3	NYnkSJFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\uTWM2OD12OT6zPFk{KM7:TR?=	M1fWXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzPTZ2NUmvK\|5USU6JRWK8M4E,
PC3	NYnncYJITnWwY4Tpc44h[XO\|YYm=	NFvKT2lKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDpckBpfW2jbjDQR\|Mh[2WubIOg[ZhxemW\|c3nu[{BCc3RzIGO0O\|NFKG23dHHueEBie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTpc44hd2ZiQXv0JHRpejNyODDifUBqdW23bn;icI91fGmwZzygSWM2OCB;IEGuPEDPxE1w	MmnpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|MkK1OlYoRjJzM{KyOVY3RC:jPh?=
TC32	NVrYVVVUeUiWUzDhd5NigQ>?	M2r4PZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy\|	M4TQNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	MmqxdWhVWyCjc4PhfS=>	NGW5OVVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	M3HDOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	NY\zfJBoeUiWUzDhd5NigQ>?	NVLId\|hGeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	Mn7vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	M4LOOJFJXFNiYYPzZZk>	NUnZNmhKeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	NWr1TVc{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NFOx[2lyUFSVIHHzd4F6	MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	NIT2eI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NEDme3JyUFSVIHHzd4F6	MorCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	NEjVbpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NILKSXByUFSVIHHzd4F6	MX\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	Mo\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	NXvkW21leUiWUzDhd5NigQ>?	M3jKfZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	MmPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NV3ibZBEeUiWUzDhd5NigQ>?	NGfVVmZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy\|	NXjtVIlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	NWnpO2ZneUiWUzDhd5NigQ>?	NWDQSnBFeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	NG\Jcmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	ATF4 / p-S6K(T389) / S6K / p-eIF2α(S51) / eIF2α / 4EBP1 / eIF3b; PubMed: 28494858 Cell Rep 4E-BPs are required for mTOR control of ATF4. 4E-BP1/2 wild-type (WT), double knockout (DKO), or DKO MEFs stably expressing 4ebp1 (DKO + 4ebp1) were treated with vehicle (DMSO) or 250 nM Torin 1 for 4 hr. Cell extracts were analyzed by immunoblotting for the indicated proteins. LC3 / p62 / PARP / pAKT(S473) / p4EBP1(S65) / pS6K1(T389) / pS6(S235/236); PubMed: 24126619 Int J Oncol Cells were treated with increasing doses of the mTOR inhibitors, torin 1 (A) and rapamycin (B), in RPMI-1640 containing 10% FBS for 2 days. LC3 processing, p62 accumulation, PARP cleavage, AKT phosphorylation and mTOR pathway activity (indicated by phosphorylation of 4E-BP, S6K1 and S6) were analyzed by western blotting of total cell lysates. GAPDH was the control for protein loading. p-mTOR(S2481) / mTOR / rictor / Sin1 / p-Akt S473 / p-Akt T450 / p-Akt T308 / p-S6K1 T389 / S6K1; PubMed: 21965657 J Biol Chem mTOR kinase activity controls abundance of SIN1. MDA-MB-435 cells were incubated with specific mTOR inhibitor (0.5 μm TORIN) for 24 or 48 h and analyzed. Vinculin / p-S6; PubMed: 28757207 Mol Cell A375 cells were treated with Torin1 for 48 h and localization of proteins was visualized by confocal microscopy. Scale bar, 50 μm. Focal adhesion size was measured by Fiji program.	28494858 24126619 21965657 28757207
Immunofluorescence	lipin-1; PubMed: 28347999 FASEB J Inhibition of mTOR activity promoted the nuclear translocation of lipin-1. After treatment with or without torin 1 for 4 h, cells expressing HA-lipin-1 were fixed and stained with a rabbit HA antibody followed by Alexa 594–conjugated goat anti-rabbit secondary antibody. Nuclei were stained with DAPI. Scale bars, 20 μM.	28347999
Growth inhibition assay	Cell viability; PubMed: 28757207 Mol Cell Cancer cell lines were grown in complete media with/without mTOR inhibitor, Torin1 (250 nM). Media and Torin1 were replaced every 2 days and cells were counted at the indicated time points. Data are the means ± SD of three separate experiments performed in triplicate.	28757207

In vivo

Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse mTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl₂, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.
Cell Research:^[1]	- Collapse Cell lines: MEFs Concentrations: ~250 nM Incubation Time: 4 days Method: Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: U87MG xenograft model Dosages: 20 mg/kg Administration: Administered via i.p. once daily (Only for Reference)

References

[4] Dowling RJ, et al, Science, 2010, 328(5982), 1172-1176.

- Collapse

Solubility (25°C)

In vitro	DMSO	2 mg/mL (3.29 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Torin 1 SDF

Molecular Weight	607.62
Formula	C₃₅H₂₈F₃N₅O₂
CAS No.	1222998-36-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to re-constitute the inhibitor for i.p. administration?
Answer:
S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin (Compound C, BML-275) is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy. For animal testing, the water-soluble S7306 Dorsomorphin (Compound C) 2HCl is recommended.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001, SDZ-RAD) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. AZD8055 induces caspase-dependent apoptosis and also induces autophagy. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Temsirolimus (CCI-779)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.
Sapanisertib (MLN0128)

Sapanisertib (MLN0128, INK 128, TAK-228) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506, FR900506, Fujimycin, Prograf) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex. Tacrolimus also inhibits the phosphatase activity of calcineurin. Tacrolimus induces vascular endothelial autophagy.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1